Q3 2024 · 13F-HR
BML Capital Management, LLCholdings as filed
Filed 2024-11-05 · accession 0001754960-24-000545
$169.9M
Reported value
29
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 46436E718 | SGOV | ISHARES TR | $27.2M | 16.0% | 270,000 | Common | NONE |
| 45783C200 | TIL | INSTIL BIO INC | $22.6M | 13.3% | 335,000 | Common | NONE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $22.3M | 13.1% | 6,650,000 | Common | NONE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $16.4M | 9.64% | 14,250,000 | Common | NONE |
| 78468R663 | BIL | SPDR SER TR | $16.1M | 9.45% | 175,000 | Common | NONE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $15.9M | 9.37% | 2,268,064 | Common | NONE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $6.4M | 3.78% | 211,752 | Common | NONE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $6.2M | 3.62% | 5,749,432 | Common | NONE |
| 75974E103 | — | RENEO PHARMACEUTICALS INC | $5.9M | 3.46% | 3,457,395 | Common | NONE |
| 68403P203 | ORMP | ORAMED PHARMACEUTICALS INC | $5.3M | 3.14% | 2,186,191 | Common | NONE |
| 00449L102 | 698 | ACHILLES THERAPEUTICS PLC | $4.2M | 2.46% | 4,100,002 | Common | NONE |
| 00032Q104 | WHWK | AADI BIOSCIENCE INC | $4.1M | 2.42% | 2,000,000 | Common | NONE |
| 207523101 | — | CONNECT BIOPHARMA HLDGS LTD | $3.0M | 1.77% | 2,093,232 | Common | NONE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $2.5M | 1.48% | 1,688,772 | Common | NONE |
| 046484309 | ASTC | ASTROTECH CORP | $1.8M | 1.04% | 220,410 | Common | NONE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $1.7M | 1.02% | 1,136,091 | Common | NONE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $1.4M | 0.84% | 60,000 | Common | NONE |
| 45175G108 | — | IKENA ONCOLOGY INC | $1.3M | 0.74% | 723,288 | Common | NONE |
| 921659108 | VNDA | VANDA PHARMACEUTICALS INC | $1.1M | 0.63% | 228,500 | Common | NONE |
| 128058302 | LSTA | LISATA THERAPEUTICS INC | $854,007 | 0.50% | 284,669 | Common | NONE |
| 720795202 | — | PIERIS PHARMACEUTICALS INC | $698,515 | 0.41% | 42,130 | Common | NONE |
| 38942Q202 | CALC | CALCIMEDICA INC | $681,719 | 0.40% | 153,887 | Common | NONE |
| 019818103 | — | ALLOVIR INC | $487,595 | 0.29% | 603,086 | Common | NONE |
| 87424L207 | TLIS | TALIS BIOMEDICAL CORP | $460,099 | 0.27% | 248,702 | Common | NONE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $451,500 | 0.27% | 150,000 | Common | NONE |
| 34962G208 | FBRX | FORTE BIOSCIENCES INC | $393,916 | 0.23% | 70,468 | Common | NONE |
| 65343E108 | NXTCEUR | NEXTCURE INC | $378,757 | 0.22% | 276,465 | Common | NONE |
| 92511W108 | — | VERRICA PHARMACEUTICALS INC | $261,000 | 0.15% | 180,000 | Common | NONE |
| 43157M102 | — | HILLEVAX INC | $34,778 | 0.02% | 19,760 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.